医学交流课件：Disease management status of COPD patients in China.pptxVIP

Disease management status of COPD patients in China Improving and data mining of the Database of China Pulmonary Health Study;Background;Background;Inclusion Criteria of the survey;Questionnaire of the survey; Current status of the database: All paper version questionnaires had been collected and restored in Beijing center. All data of PTF test, questionnaire and clinical examinations had been collected into the raw database, which needs to be cleaned ASAP. This database will also allow us to study the disease management status of COPD patients in China, which will help improve COPD management in the future. Study type: ESR ;Chen WANG, M.D., Ph.D., FCCP Professor of Pulmonary ＆ Critical Care Medicine Member of the Chinese Academy of Engineering President of China-Japan Friendship Hospital Associate Director of Beijing Institute of Respiratory Medicine Chair of Department of Respiratory Medicine, Capital Medical University Specialist Area and Research Interest Pulmonary embolism pulmonary vascular diseases; Emerging contagious respiratory diseases; Chronic obstructive pulmonary diseases; Respiratory failure mechanical ventilation: Tobacco control tobacco cessation. Selected Clinical Research Experience CHEST-1 Study: Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension, 2011, Steering Committee Member The LIFENOX study: Low-molecular-weight heparin prophylaxis and mortality in acutely ill medical patients, 2009, Steering Committee Member Clinical Features Study of the Initial Cases of 2009 Pandemic Influenza A (H1N1) Virus Infection in China, 2009, PI A prospective study on health related quality of life of COPD patients, 2003, PI Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary Thromboembolism: A Randomized, Multicenter, Controlled Trial, 2002, PI ;Objectives Endpoints;Raw database of CPHS;Data Cleaning;Analysis: Management of COPD; Prevalence of COPD are 2.5% a